Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 16, 2010

Bar Harbor BioTechnology Gains PCR and Real-Time PCR Patents from Life Technologies

  • Bar Harbor BioTechnology (BHB) has entered into a license agreement with Life Technologies to offer contract research services related to data collection and analysis based on the StellARray™ and XenoQ™ systems.

    “We wanted to make our expertise in assay design available to all genetic researchers and provide excellent quality data,” states Robert Phelps, CEO of BHB. Researchers purchasing StellARrays or XenoQ assays through Lonza, their exclusive distributor, can now contract BHB to perform real-time PCR services.

    The data generated in the experiments will be analyzed using BHB’s Global Pattern Recognition™ analysis software. The company has expanded its staff to provide the new services secured in this agreement.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »